Novartis Achieves Primary Endpoint in Phase III Trial
Novartis announced that Fabhalta® (iptacopan) has met its primary endpoint in a Phase III trial, demonstrating its ability to slow kidney function decline in patients with IgA nephropathy (IgAN).
Novartis is a leading medicines company that aims to improve and extend people's lives through innovative treatments, reaching 296 million people worldwide.
- Clinical trial recruiting and managed access programs for patients and caregivers
- Grant funding, congresses, and country-level information for healthcare professionals
Our goal is to empower patients, healthcare professionals, and societies in the face of serious disease.
About Novartis
Novartis is committed to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards.
Author's summary: Novartis achieves milestone in IgAN treatment.
More News
- Scott Parker Newcastle Press Conference
- As Durham crime rates fall, city remains vigilant
- View from the Opposition: Scott Parker on the challenge Palace pose
- Analysis: Spirited response can't mask issues at both ends
- Durham University
- Newcastle 2-1 Burnley: Scott Parker post-match interview
- Marvin Vettori's Comeback: Aiming to End His Three-Fight Skid at UFC 323
- Durham Osteopathy Receives 2025 Consumer Choice Award
- Newcastle 2-1 Burnley: What Parker said
- Durham Council Delays Major Development at Former Police Headquarters